PER-055-04已完成未知
MULTI-CENTER STUDY IN PHASE III, RANDOMIZED, OF THREE BRANCHES, DOUBLE-BLIND CONTROLLED WITH A PARALLEL ACTIVE GROUP TO EVALUATE THE SAFETY AND EFFICACY OF MURAGLITAZAR COMBINED WITH METFORMIN COMPARED WITH GLIMEPIRIDE COMBINED WITH METFORMIN IN PATIENTS WITH DIABETES TYPE 2 THAT HAVE INAPPROPRIATE CONTROL OF THE GLUCEMIA TO BE TREATED WITH METFORMIN AS MONOTHERAPY
试验速览
- 阶段
- 未知
- 状态
- 已完成
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 0 至 0（—）
入选标准
- •Subject with Type 2 diabetes receiving treatment with at least 1,500 mg but not greater than 3000 mg of stable metformin therapy for at least 6 weeks prior to screening
- •HbA1c >or = 7% and < or = 10%
- •Fasting c-peptide > or = 1.0 umol
- •Body Mass Index < or = 41 kg/m2
- •Mean serum triglycerides < or = 600 mg/dl
排除标准
- •1. History of diabetic ketoacidosis, hyperosmolar non-ketotic coma or insulin treatment within one year of selection.
- •2. Symptomatic type 2 diabetes, defined by polyuria and polydipsia with weight loss greater than 10% during the last three months.
- •3. History of myocardial infarction (MI), coronary angioplasty, or bypass graft (s), valvular disease or repair, unstable angina, TIA, or cerebrovascular accidents, within six months prior to entering the study.
研究者
相似试验
进行中（未招募）
1 期
RANDOMIZED PHASE III MULTICENTRE STUDY INVESTIGATING THE ROLE OF LETROZOLE IN HEAVILY PRETREATED RECURRENT OVARIAN CANCERADVANCED OVARIAN CANCERMedDRA version: 21.1Level: PTClassification code 10054913Term: Serous cystadenocarcinoma ovarySystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2019-001623-12-ITFONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE236
已完成
不适用
Paclitaxel With / Without GW572016 (Lapatinib) As First Line Therapy For Women With Advanced Or Metastatic Breast Cancer-C50 Malignant neoplasm of breastMalignant neoplasm of breastC50PER-045-04GLAXOSMITHKLINE PERU S.A.,40
进行中（未招募）
不适用
RANDOMIZED MULTICENTER PHASE III STUDY IN PATIENTS WITH LOCALLY ADVANCED ADENOCARCINOMA OF THE PANCREAS: GEMCITABINE WITH OR WITHOUT CHEMORADIOTHERAPY AND WITH OR WITHOUT ERLOTINIB - LAP 07Patients with de novo locally advanced, histologically proven adenocarcinoma of the pancreas without distant metastases (stage III according to the UICC classification) and not considered for curative resection after pluridisciplinary discussion.MedDRA version: 9.1Level: LLTClassification code 10052747Term: Adenocarcinoma pancreasEUCTR2007-001174-81-FRGERCOR820
进行中（未招募）
1 期
RANDOMIZED MULTICENTER PHASE III STUDY IN PATIENTS WITH LOCALLY ADVANCED ADENOCARCINOMA OF THE PANCREAS: GEMCITABINE WITH OR WITHOUT CHEMORADIOTHERAPY AND WITH OR WITHOUT ERLOTINIB - GERCOR - LAP 07EUCTR2007-001174-81-SEGOF pancreatic cancer collaborative group442
进行中（未招募）
1 期
RANDOMIZED MULTICENTER PHASE III STUDY IN PATIENTS WITH LOCALLY ADVANCED ADENOCARCINOMA OF THE PANCREAS: GEMCITABINE WITH OR WITHOUT CHEMORADIOTHERAPY AND WITH OR WITHOUT ERLOTINIB - LAP 07EUCTR2007-001174-81-BEB Erasme Hospital902